Roth Mkm Downgrades Acer Therapeutics (NASDAQ:ACER) to Neutral

Roth Mkm lowered shares of Acer Therapeutics (NASDAQ:ACER – Free Report) from a buy rating to a neutral rating in a research note published on Friday, MarketBeat reports. Roth Mkm currently has $1.50 price target on the biopharmaceutical company’s stock. Acer Therapeutics Trading Down 10.9 % Acer Therapeutics stock opened at $1.14 on Friday. The […]

Related Keywords

Roth Mkm ,Meridian Wealth Management ,Armistice Capital ,Renaissance Technologies ,Acer Therapeutics Company Profile ,Acer Therapeutics Inc ,Hunter Associates Investment Management ,Acer Therapeutics ,Free Report ,Therapeutics Trading Down ,Get Free Report ,Bay Capital Management ,Associates Investment Management ,Therapeutics Inc ,Ehlers Danlos Syndrome ,Vasomotor Symptoms ,Acer Therapeutics Daily ,Nasdaq Acer ,Acer ,Medical ,Downgrade ,